Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Benlek
The product does not meet the required quality specifications due to a negative result for the parameter “Chromatographic purity of thiamine hydrochloride”, indicating the presence of undesirable impurities. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.
Tranexamic acid injection BP
A quality defect was found: the ampoule cannot be opened normally, it crumbles, and it is uncertain whether glass fragments have entered the inside and contaminated the solution, creating a risk of administering a medicinal product containing glass to the patient. Potential effects: poisoning, tissue damage, life-threatening complications.
Vendal retard
Due to morphine being released in a different amount than specified in the documentation, the impact on the course of therapy and the suspicion of a threat to the patient’s health or life cannot be excluded. Potential effects: overdose or insufficient analgesic effect, dependence, life-threatening complications.
Aciclovir Jelfa
Due to the detected presence of particles visible to the naked eye, a risk to the patient’s health or life cannot be excluded. Potential effects: complications after intravenous administration, vessel damage, embolism, severe systemic reactions.
Tresuvi
The presence of unidentified solid particles was found in the product, and the nature of the contamination and its cause have not been determined. Therefore, a risk to the patient’s health and life cannot be excluded. Potential effects: infusion complications, embolism, inflammatory reactions, life‑threatening events.
Amikacin B.Braun
Cross-contamination of infusion solutions was detected in the specified batches of medicinal products. Potential effects: poisoning, adverse reactions, infectious complications or lack of treatment efficacy.
Amikacin B.Braun
Cross-contamination of infusion solutions was found in many batches of B. Braun medicinal products, which may mean the presence of an incorrect active substance or its traces in intravenously administered preparations. Potential effects: poisoning, severe adverse reactions, lack of treatment efficacy.
Amikacin B.Braun
Cross-contamination of infusion solutions in the listed medicinal product batches was detected, which may mean the presence of incorrect substances in the medicine. Potential effects: poisoning, lack of treatment efficacy, serious complications.
Gentamicin B.Braun
Cross-contamination of infusion solutions was identified in numerous batches of B. Braun products, meaning the presence of incorrect active substances or their residues in bottles intended for intravenous administration, breaching quality and safety requirements. Potential effects: severe adverse reactions, poisoning, lack of efficacy or complications of intravenous therapy.
Gentamicin B.Braun
Cross-contamination of infusion solutions in the specified batches of B. Braun medicinal products was detected and reported in the Rapid Alert system by the Hessian State Office for Health and Care. Potential effects: risk of incorrect dosing, toxicity, lack of therapeutic efficacy or serious complications after intravenous administration.
Metronidazole B. Braun
Cross-contamination of infusion solutions in the listed batches of B. Braun medicinal products was detected. Potential effects: poisoning, severe adverse reactions, lack of therapeutic efficacy.
Ibuprofen B. Braun
Cross-contamination of infusion solutions in selected batches of medicinal products was found, which may result in administration of an unintended active substance to the patient and complications during intravenous treatment. Potential effects: poisoning, severe adverse reactions, lack of treatment efficacy.
Ibuprofen B. Braun
Cross-contamination of infusion solutions in the listed batches of B. Braun medicinal products was detected and reported via the Rapid Alert system by the German pharmaceutical authority. Potential effects: possible severe adverse reactions, poisoning, lack of therapeutic efficacy or infusion-related complications.
Ibuprofen B. Braun
Cross-contamination of infusion solutions was found in the listed batches of B. Braun medicinal products, reported via the Rapid Alert system by the Hessisches Landesamt für Gesundheit und Pflege as potentially endangering the safety of intravenous therapy. Potential effects: poisoning, severe adverse reactions, lack of efficacy, treatment complications.
Fluconazole B. Braun 2 mg/ml
Cross‑contamination of infusion solutions was detected in the above-mentioned medicinal product batches, which may lead to administration of an incorrect substance or dose to the patient. Potential effects: poisoning, serious adverse reactions, allergic reactions, lack of efficacy, severe systemic complications.
Paracetamol B. Braun
detection of cross-contamination of infusion solutions in the above-mentioned series of medicinal products Potential effects: poisoning, unpredictable adverse reactions, lack of therapeutic efficacy, perioperative complications.
Lactulose-MIP
A deviation in the manufacturing process was identified; deterioration of product quality during the shelf life cannot be excluded, thus creating a risk to patient health. Potential effects: lack of therapeutic efficacy or adverse reactions.
Lactulose-MIP
Deviations were identified in the product manufacturing process, so deterioration of its quality during the shelf life cannot be excluded, and therefore there is a potential risk to patient health. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.
Sabril
Due to the detected presence of tiapride, a risk to the patient’s health or life cannot be excluded; the presence of trace amounts of tiapride may theoretically result in numerous serious and life‑threatening adverse reactions. Potential effects: severe, potentially life‑threatening adverse reactions.
Sabril
The presence of tiapride above 0.3 ppm in vigabatrin products may theoretically lead to numerous serious and life‑threatening adverse reactions; a risk to the patient’s health or life cannot be excluded. Potential effects: serious adverse reactions, including life‑threatening events.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.